Investigation of FCPA Violations in Europe

We represented a Fortune 500 company in the life sciences industry in an investigation by the U.S. Department of Justice and Securities and Exchange Commission of alleged FCPA and local law violations relating to the company’s operations in Europe and conduct of its distributors. This representation included providing guidance and advice about the pros and cons of self-reporting, the potential value of cooperation, and benefits of remedial actions taken to enhance the existing compliance program.

You Also May Be Interested In:

  • We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc., emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.

     

    We represented BioScrip, Inc. in its merger with Option Care Enterprises, Inc. The newly combined company, Option Care Health, Inc.,...
    Client Type: Public Company
  • Represented Quest Diagnostics in its acquisition of Mobile Medical Examination Service

    We represented Quest Diagnostics (NYSE: DGX) in its acquisition of Mobile Medical Examination Service (MedXM), a leading national provider of...
    Client Type: Public Company
  • Represented Quest Diagnostics in its acquisition of Cleveland HeartLab

    We represented Quest Diagnostics (NYSE: DGX) in its acquisition of Cleveland HeartLab. The acquisition combines the expertise of Cleveland HeartLab's...
    Client Type: Public Company